Topical Bimatoprost Solution 0.

03%in Stable Vitiligo

Verified by: Gian Sagar Medical College and Hospital, July 2010
First Received: September 14, 2010 | Last Updated: August 2, 2011 | Phase: Phase 4 | Start Date: August 2010
Overall Status: Withdrawn | Estimated Enrollment: 20
Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population.
Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives are basic treatment
modalities have been used in vitiligo but there is still no effective and safe treatment for this disease. Resistance to therapy,
treatment...

Brief Summary

Official Title: “Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study”

Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population.
Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives are basic treatment
modalities have been used in vitiligo but there is still no effective and safe treatment for this disease.

Resistance to therapy, treatment complications and recurrence after treatment are the major problems of the current treatments.

There are no clinical studies of use of Bimatoprost in treatment of vitiligo, as it is supposed to cause more hyperpigmentation and
hypertrichosis as compared to other topical prostaglandin analogues; hence, the investigators decided to use it in treatment of
localized vitiligo.

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group
Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Study Primary Completion Date: November 2010

Detailed Clinical Trial Description

Vitiligo is an acquired depigmentation disorder of great cosmetic importance, affecting 1-4% of the world's population. Vitiligo
does not cause physical symptoms but because of its unsightly appearance, particularly on dark or tanned skin it can have
considerable impact both psychologically and socially. Many ways of restoring normal colour to the skin have been tried but
improvement is usually short-lived. The causes of vitiligo are not yet clearly understood, so many treatments have been developed
on the basis of limited scientific evidence. There is no cure, and no way of limiting the spread of the disease has so far been
found.

The pathogenetic basis of the disease is melanocyte disappearance from achromic patches and experimental evidence has shown
that three possible mechanisms enable this to occur: an apoptotic process, a necrotic event, and melanocythoragy following
trauma due to impaired function of cell-cell or cell-matrix adhesion.

Prostaglandins (PGs) are biologically active derivatives of 20 carbon atom polyunsaturated essential fatty acids released from cell
membrane phospholipids. PGE2 and PGF2 are primary PGs. PGE2 is synthesized in skin and affects keratinocytes, Langerhans
cells and melanocytes and regulates melanocyte proliferation. Epidermal melanocytes synthesize melanin in response to ultraviolet
radiation (UVR). The mechanisms mediating the UVR-induced activation of melanogenesis are unknown but, as UVR induces the
turnover of membrane phospholipids generating prostaglandins (PGs) and other products, it is possible that one of these might
provide the activating signal. 1 In an in vitro study by Tomita et al .,2 normal human epidermal melanocytes became swollen and
more dendritic when they were cultured with prostaglandin E 2 (PGE 2), but not with PGE 1. In another study by Nordlund et al .,
3 PGE2 applied topically to mice skin caused an increase in melanocyte density.
Histologic studies indicate that PGE 2 also enhances melanogenesis. Recently, there have been many reports of iris darkening,
hyperpigmentation of the eyelashes, and periocular hyperpigmentation induced by latanoprost . (prostaglandin F 2 α , used for the
treatment of glaucoma). 4,5 Although the exact mechanism of this pigmentation is not clear, different mechanisms of the induction
of hyperpigmentation by prostaglandins have been suggested, including: (i) influencing the responsiveness of melanocytes to
neuronal stimuli; (ii) causing melanocyte proliferation; and (iii) a direct or second messenger mediated interaction with melanocytes
via the stimulation of tyrosinase activity.

Phototherapy and topical agents such as corticosteroids, calcineurin inhibitors, and vitamin-D derivatives are basic treatment
modalities have been used in vitiligo but there is still no effective and safe treatment for this disease. Resistance to therapy,
treatment complications and recurrence after treatment are the major problems of the current treatments.

There are no clinical studies of use of Bimatoprost 0.03% in treatment of vitiligo, as it is supposed to cause more
hyperpigmentation and hypertrichosis as compared to other topical prostaglandin analogues, hence, we decided to use it in
treatment of localized vitiligo.

Aim:

In this study, twenty patients with vitiligo will be treated with topical Bimatoprost o.o3% ophthalmic solution for 4 months to
elucidate its efficacy and tolerability in stable vitiligo.

Patients and methods In this prospective, interventional, non-randomised, single blind, controlled study, twenty patients with
stable vitiligo will be enrolled from the Dermatology out patient department of Gian Sagar Medical College and Hospital. The
protocol will follow the Declaration of Helsinki and prior approval of Institutional Review Board will be obtained. Informed
consent will be obtained from all patients. Detailed history and physical examination will be obtained. The age, sex, previous
treatments, family history, type of vitiligo, durations of disease (in month), areas of involvement, Koebner phenomenon,
leukotrichia will be recorded in special data sheet. The diagnosis of vitiligo will be made clinically. No concomitant treatment will
be allowed and a washout period of at least 1 month will be given in patients using other therapies.

Patients will be instructed to apply a Bimatoprost 0.03% solution twice daily to the depigmented skin taking care of no spillage to
surrounding skin. The dimensions of the treated lesions will be measured in transverse and longitudinal axes at the time of
enrollment, subsequently every month till 4 months.

The measurement of the lesions will be performed by an independent observer who is blind to the treatment options. Photography
will be done using a digital camera (Sony Digital Still Camera Cyber-shot ModelNO DSCF 717, Tokyo, Japan) at the baseline and
at every follow up visit. Patients will be evaluated by the same observer who was blind to the treatment options.

Primary Outcome Measures:

The percentage of repigmentation in the previously depigmented patch, in form of color or size changes and folliculocentric
repigmentation, of the treated and the control patches.6

Depending on the extent of repigmentation, the response to the treatment will be graded as: - no and minimal (<25%), - moderate
(25-49%), - marked (50-74%), - excellent (75-99%), and - complete (100%) response. Response without reduction of the surface
and only with perifollicular hyperpigmentation will be categorized as perifollicular pigmentation.

Responding lesions will be defined as patches that achieved more than 50% repigmentation as compared with the baseline.
Treatment will be discontinued if patients did not show any improvement or worsening at 2 months.

Intervention(s) in this Clinical Trial

 Drug: Bimatoprost 0.03% topical ophthalmic solution

Arms, Groups and Cohorts in this Clinical Trial

Experimental: Bimatoprost application

Outcome Measures for this Clinical Trial

Primary Measures

repigmentation in the previously depigmented patch

Time Frame: 4 months
Safety Issue?: Yes
Secondary Measures

safety profile of Topical Bimatoprost solution

Time Frame: 4 month
Safety Issue?: Yes

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

1. Patient of either sex and at least 10 years old

2. Have a diagnosis of vitiligo with no news lesions or growth of old lesions in the past 6 months
3. Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form
4. Agree to follow and undergo all study-related procedures
Exclusion Criteria:

1. Patients showing evidence of spontaneous repigmentation in any of the lesions

2. Patients with rapidly progressive disease were also excluded.
3. Patients with hypersensitivity to the drug or any of its constituents
4. Patients with BSA > 5%
Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 10 Years

Maximum Age for this Clinical Trial: 40 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: Gian Sagar Medical College and Hospital Other

Overall Clinical Trial Officials and Contacts

Rajeev Jain, M.D. Study Director PP

Related Publications

References
Friedmann PS, Wren FE, Matthews JN. Ultraviolet stimulated melanogenesis by human melanocytes is augmented by di-acyl
glycerol but not TPA. J Cell Physiol. 1990 Feb;142(2):334-41.

Nordlund JJ, Collins CE, Rheins LA. Prostaglandin E2 and D2 but not MSH stimulate the proliferation of pigment cells in the
pinnal epidermis of the DBA/2 mouse. J Invest Dermatol. 1986 Apr;86(4):433-7.

Wand M, Ritch R, Isbey EK Jr, Zimmerman TJ. Latanoprost and periocular skin color changes. Arch Ophthalmol. 2001
Apr;119(4):614-5. No abstract available.

Prota G, Vincensi MR, Napolitano A, Selen G, Stjernschantz J. Latanoprost stimulates eumelanogenesis in iridial melanocytes of
cynomolgus monkeys. Pigment Cell Res. 2000 Jun;13(3):147-50.

Hossain D. Assessment scale used in vitiligo. J Am Acad Dermatol. 2005 Jun;52(6):1110-1. No abstract available.

Tomita Y, Iwamoto M, Masuda T, Tagami H. Stimulatory effect of prostaglandin E2 on the configuration of normal human
melanocytes in vitro. J Invest Dermatol. 1987 Sep;89(3):299-301.

Additional Information
Information obtained from ClinicalTrials.gov on August 04, 2011
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT01202513
Study ID Number: GSMCH230810
ClinicalTrials.gov Identifier: NCT01202513
Health Authority: India: Institutional Review Board

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of
specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:

http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01202513

This clinical trials RSS facility is brought to you as a free service by Clinical Trials Feeds (ClinicalTrialsFeeds.org), using data supplied by the US National Institutes of Health and

ClinicalTrials.gov. You can also check our CR Health Net partner site DrugInserts.com for an easy-to-use database of the latest product labels and medication package inserts from the US

Food and Drug Administration.